Acorda Therapeutics Inc (ACOR) is a publicly traded drug manufacturers-specialty and generic business based in the US. On 13 September Acorda Therapeutics shares leapt 10.90% to a closing position of $14.86. However, over the last 12 months, Acorda Therapeutics's share price has fallen by 8.57% from $5.72 (accounting for the 5 June 2023 split). Acorda Therapeutics is listed on the NASDAQ and employs 111 staff. All prices are listed in US Dollars.
Best for
0% commission
Best for
Beginner investments
Best for
Beginners
Best for
Low fees
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Customer rating | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|---|
|
★★★★★ | £0 - £9.99 | No minimum | £2.53 £430.97 total |
Capital at risk |
|
★★★★★ | £0 | $50 | £2.14 £430.58 total |
Capital at risk |
|
★★★★★ | £0 | £250 | £10.38 £438.82 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £2.14 £430.58 total |
Capital at risk |
 |
Not yet rated | £0 | No minimum | £2.14 £430.58 total |
Capital at risk |
 |
★★★★★ | £0 | £1 | £16.23 £444.68 total |
Capital at risk |
|
Not yet rated | £0 | No minimum | £1.58 £430.02 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Acorda Therapeutics P/E ratio, PEG ratio and EBITDA
Acorda Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Acorda Therapeutics shares trade at around 2x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Acorda Therapeutics's P/E ratio is best considered in relation to those of others within the drug manufacturers-specialty & generic industry or those of similar companies.
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Acorda Therapeutics's PEG ratio in relation to those of similar companies.
Acorda Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.5 million (£0.0 million).
The EBITDA is a measure of a Acorda Therapeutics's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Join 50,000 subscribers who are notified about expert share tips. Plus a chance to win £500!
By signing up you agree to receive emails from Finder and to the privacy policy and terms & conditions.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Exelixis? We explain how and compare a range of providers that can give you access to many brands, including Exelixis.
Ever wondered how to buy shares in Five Star Senior Living? We explain how and compare a range of providers that can give you access to many brands, including Five Star Senior Living.
Ever wondered how to buy shares in Community Health Systems? We explain how and compare a range of providers that can give you access to many brands, including Community Health Systems.
Ever wondered how to buy shares in Chiasma? We explain how and compare a range of providers that can give you access to many brands, including Chiasma.
Ever wondered how to buy shares in Healthcare Services Group? We explain how and compare a range of providers that can give you access to many brands, including Healthcare Services Group.
Ever wondered how to buy shares in Catalent? We explain how and compare a range of providers that can give you access to many brands, including Catalent.
Ever wondered how to buy shares in Aytu BioScience? We explain how and compare a range of providers that can give you access to many brands, including Aytu BioScience.
Ever wondered how to buy shares in bluebird bio? We explain how and compare a range of providers that can give you access to many brands, including bluebird bio.
Ever wondered how to buy shares in LHC Group? We explain how and compare a range of providers that can give you access to many brands, including LHC Group.
Ever wondered how to buy shares in Amneal Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Amneal Pharmaceuticals.